	US 12,110,342 B2
	Nucleic acid monoclonal antibodies targeting PCSK9 and methods of use
David Weiner, Merion, PA (US); Makan Khoshnejad, Philadelphia, PA (US); Kar Muthumani, Cherry Hill, NJ (US); and Ami Patel, Philadelphia, PA (US)
Assigned to THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, Philadelphia, PA (US)
Appl. No. 16/966,513
Filed by THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY, Philadelphia, PA (US)
PCT Filed Jan. 31, 2019, PCT No. PCT/US2019/015972 § 371(c)(1), (2) Date Jul. 31, 2020, PCT Pub. No. WO2019/152599, PCT Pub. Date Aug. 8, 2019.
Claims priority of provisional application 62/624,297, filed on Jan. 31, 2018.
Prior Publication US 2020/0362055 A1, Nov. 19, 2020
Int. Cl. C07K 16/40 (2006.01); A61P 3/06 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/40 (2013.01) [A61P 3/06 (2018.01); A61K 2039/505 (2013.01)]

14 Claims

1. A composition for generating one or more anti-PCSK9 antibodies or antigen-binding fragments thereof in a subject, comprising one or more nucleic acid molecules encoding one or more anti-PCSK9 antibodies or antigen-binding fragments thereof;

wherein the composition comprises:

a) a nucleotide sequence encoding an amino acid sequence having at least about 99% identity over the entire length of at least one amino acid sequence selected from the group of SEQ ID NOs: 1, 3, 5 and 7, wherein the encoded CDRs comprises 100% identity to the CDRs of SEQ ID NO: 1, 3, 5 or 7;

b) a nucleotide sequence having at least about 99% identity over the entire length of at least one nucleotide sequence selected from the group of SEQ ID NOs: 2, 4, 6 and 8, wherein the nucleotide sequences encoding the CDRs comprises 100% identity to the CDR coding sequences of SEQ ID NO:2, 4, 6 and 8; or c) any combination thereof.